

## April Funding Update

**SYDNEY, Australia, 28 March 2018:** Recce Pharmaceuticals Ltd (ASX: RCE) (**Recce** or the **Company**), developing a new class of synthetic antibiotics, today advises that in view of the Company's current liquidity and the imminent receipt of a further AU\$853,000 from the Federal Government under its R&D rebate scheme, the Board believes the Company has sufficient funds to meet its near-term objectives as it continues to maintain a prudent and cautious approach to managing its finances. Thus, it has decided to exercise its right to defer the next AU\$50,000 equity investment from the Australian Special Opportunity Fund managed by The Lind Partners under its AU\$6.05 million funding agreement executed in 2017.

### Background to the Federal Government rebate

As announced to the market in January 2018, the Federal Government confirmed the allocation of AU\$2.43 million to the Company, in the form of 43.5 per cent rebates on AU\$5,605,709 of the Company's international research and development expenditure (FY17/18/19), on top of an existing 43.5 per cent rebate Recce receives for local research and development.

### Background to The Lind Partners funding agreement

In June 2017 Recce entered into a funding agreement of up to AU\$6.05 million with The Australian Special Opportunity Fund LP, a New York institutional investor managed by The Lind Partners. The agreement allows the Company to pause investment or terminate the agreement without penalty at any time and is structured to provide capital in advance on a monthly basis, minimising shareholder dilution.



ASX: RCE

**Head Office** Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (0)2 8075 4585 **F** +61 (0)2 8075 4584

**R&D Centre - Perth** Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899

**Washington Office** 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

## About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a [new class of synthetic antibiotics with broad spectrum activity](#) designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results. Recce has a manufacturing facility in Australia and is developing clinical research partners in the USA. The Company has developed an automated process to manufacture its lead compound ahead of first-in-man clinical trials.

---

For further information please visit [www.recce.com.au](http://www.recce.com.au) or contact:

### Investor Relations

James Graham  
Executive Director  
Recce Pharmaceuticals Ltd  
Tel: +61 (02) 8075 4585

### Media (Australia)

Andrew Geddes  
CityPR  
Tel: +61 (02) 9267 4511

### Media (International)

Sue Charles/Gemma Harris  
Instinctif Partners  
Tel: +44 (0)20 7866 7860  
E: [recce@instinctif.com](mailto:recce@instinctif.com)

